The use of anti-hyperglycemic drugs such as pioglitazone, glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors had raised expectations for their potential efficacy in improving NAFLD. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.